Header Logo

Connection

WILLIAM FISHER to Bevacizumab

Back to Details
This is a "connection" page, showing publications WILLIAM FISHER has written about Bevacizumab.
WILLIAM FISHER
Connection Strength
0.018
Bevacizumab
  1. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemona?ve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol. 2010 Nov; 5(11):1815-20.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.